Intuitive Surgical, Inc. $ISRG Shares Bought by IQ EQ FUND MANAGEMENT IRELAND Ltd

IQ EQ FUND MANAGEMENT IRELAND Ltd raised its position in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 31.1% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 2,136 shares of the medical equipment provider’s stock after purchasing an additional 507 shares during the period. IQ EQ FUND MANAGEMENT IRELAND Ltd’s holdings in Intuitive Surgical were worth $1,161,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also modified their holdings of ISRG. Aaron Wealth Advisors LLC raised its stake in Intuitive Surgical by 0.8% in the second quarter. Aaron Wealth Advisors LLC now owns 2,528 shares of the medical equipment provider’s stock valued at $1,374,000 after buying an additional 19 shares in the last quarter. FSM Wealth Advisors LLC boosted its position in shares of Intuitive Surgical by 3.8% during the 1st quarter. FSM Wealth Advisors LLC now owns 546 shares of the medical equipment provider’s stock worth $270,000 after acquiring an additional 20 shares in the last quarter. CFO4Life Group LLC increased its holdings in shares of Intuitive Surgical by 4.8% in the 1st quarter. CFO4Life Group LLC now owns 436 shares of the medical equipment provider’s stock valued at $216,000 after acquiring an additional 20 shares during the last quarter. J. W. Coons Advisors LLC raised its position in shares of Intuitive Surgical by 1.4% during the 1st quarter. J. W. Coons Advisors LLC now owns 1,497 shares of the medical equipment provider’s stock worth $741,000 after acquiring an additional 20 shares in the last quarter. Finally, Exencial Wealth Advisors LLC lifted its stake in Intuitive Surgical by 3.1% during the first quarter. Exencial Wealth Advisors LLC now owns 661 shares of the medical equipment provider’s stock worth $327,000 after purchasing an additional 20 shares during the last quarter. 83.64% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

ISRG has been the topic of several recent analyst reports. Sanford C. Bernstein reiterated an “outperform” rating and issued a $685.00 price target on shares of Intuitive Surgical in a research note on Tuesday, October 21st. Piper Sandler upped their target price on shares of Intuitive Surgical from $595.00 to $610.00 and gave the company an “overweight” rating in a report on Wednesday, October 22nd. Hsbc Global Res raised shares of Intuitive Surgical to a “strong-buy” rating in a research report on Thursday, October 23rd. Royal Bank Of Canada set a $625.00 price target on shares of Intuitive Surgical and gave the company an “outperform” rating in a research report on Wednesday, October 22nd. Finally, Weiss Ratings restated a “hold (c+)” rating on shares of Intuitive Surgical in a research note on Wednesday, October 8th. Two analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $608.92.

Intuitive Surgical Price Performance

ISRG stock opened at $545.39 on Wednesday. The company has a fifty day moving average price of $460.82 and a 200 day moving average price of $497.70. Intuitive Surgical, Inc. has a 12 month low of $425.00 and a 12 month high of $616.00. The company has a market cap of $195.51 billion, a price-to-earnings ratio of 72.14, a price-to-earnings-growth ratio of 5.07 and a beta of 1.61.

Intuitive Surgical (NASDAQ:ISRG) last released its quarterly earnings results on Tuesday, October 21st. The medical equipment provider reported $2.40 EPS for the quarter, beating the consensus estimate of $1.99 by $0.41. Intuitive Surgical had a net margin of 28.58% and a return on equity of 15.08%. The firm had revenue of $2.51 billion during the quarter, compared to the consensus estimate of $2.41 billion. During the same quarter in the prior year, the firm earned $1.84 EPS. Intuitive Surgical’s revenue for the quarter was up 22.9% on a year-over-year basis. As a group, analysts anticipate that Intuitive Surgical, Inc. will post 6.43 earnings per share for the current year.

Insider Buying and Selling at Intuitive Surgical

In related news, Director Amy L. Ladd sold 335 shares of the company’s stock in a transaction on Thursday, September 4th. The shares were sold at an average price of $440.69, for a total value of $147,631.15. Following the completion of the sale, the director owned 739 shares in the company, valued at $325,669.91. This represents a 31.19% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Gary S. Guthart sold 2,800 shares of the company’s stock in a transaction on Friday, October 24th. The shares were sold at an average price of $546.27, for a total transaction of $1,529,556.00. Following the completion of the sale, the insider owned 17,120 shares of the company’s stock, valued at approximately $9,352,142.40. This trade represents a 14.06% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 88,324 shares of company stock worth $46,093,939 in the last 90 days. Company insiders own 0.70% of the company’s stock.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.